Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

Market Overview - The pharmaceutical commercial sector increased by 0.27% on August 21, with Guofang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Guofang Co., Ltd. (600538) closed at 6.41, up 1.91% with a trading volume of 315,600 shares and a transaction value of 202 million yuan [1] - Nanjing Pharmaceutical (600713) closed at 5.39, up 1.70% with a trading volume of 181,000 shares and a transaction value of 96.97 million yuan [1] - Shanghai Pharmaceuticals (601607) closed at 19.20, up 0.95% with a trading volume of 173,600 shares and a transaction value of 333 million yuan [1] - Yifeng Pharmacy (603939) closed at 24.49, up 0.91% with a trading volume of 88,100 shares and a transaction value of 215 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 277 million yuan from institutional investors, while retail investors saw a net inflow of 293 million yuan [2] - The data indicates that institutional investors are withdrawing capital, while retail investors are increasing their investments in the sector [2] Individual Stock Capital Flow - Nanjing Pharmaceutical saw a net inflow of 16.81 million yuan from institutional investors, while retail investors had a net outflow of 4.14 million yuan [3] - Yifeng Pharmacy experienced a net inflow of 15.49 million yuan from institutional investors, with a net outflow of 23.62 million yuan from retail investors [3] - China National Pharmaceutical (600056) had a net inflow of 8.93 million yuan from institutional investors, while retail investors had a negligible net inflow of 0.12 million yuan [3]

Market Overview - The pharmaceutical commercial sector increased by 0.05% on August 20, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.27, up 0.87% with a trading volume of 58,700 shares and a turnover of 141 million yuan [1] - Other notable performers include: - Liuyuan Group (603368) at 18.64, up 0.76% [1] - China National Pharmaceutical Group (600511) at 30.01, up 0.60% [1] - Shanghai Pharmaceuticals (601607) at 19.02, up 0.58% [1] - Nanjing Pharmaceutical (600713) at 5.30, up 0.57% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 377 million yuan from institutional investors, while retail investors saw a net inflow of 367 million yuan [2] - Notable capital flows include: - Yifeng Pharmacy had a net outflow of 9.79 million yuan from institutional investors [3] - Heavy Drug Holdings (000950) saw a net inflow of 7.45 million yuan from institutional investors [3] - Drug Easy Purchase (300937) had a net inflow of 3.82 million yuan from institutional investors [3]

Company Overview - Yifeng Pharmacy's stock price reached 24.06 yuan as of August 19, 2025, with an increase of 0.19 yuan, representing a 0.8% rise [1] - The trading volume on the same day was 94,200 hands, with a transaction value of 227 million yuan, and a fluctuation of 2.35% [1] - The company operates in the pharmaceutical retail and health management services sector, covering multiple provinces and cities across China [1] Industry Insights - Recent discussions have emerged regarding the management regulations for self-service medicine dispensing machines, with some proposals allowing prescription drug collection through these machines [1] - This potential policy change raises concerns among traditional pharmacies about cost competition and medication safety [1] - Industry experts believe that if these regulations are implemented, they could pose challenges to the operational models of traditional pharmacies [1] Financial Activity - On August 19, 2025, Yifeng Pharmacy experienced a net inflow of 14.72 million yuan in main funds, with a cumulative net inflow of 24.02 million yuan over the past five days [1]

益丰大药房连锁股份有限公司 2025 年第二次临时股东会会议资料 益丰大药房连锁股份有限公司 2025 年第二次临时股东会 会议资料 2025 年 8 月 1 / 47 益丰大药房连锁股份有限公司 2025 年第二次临时股东会会议资料 | | | | 2025 | 年第二次临时股东会会议议程····························································· | 3 | | --- | --- | --- | | 2025 | 年第二次临时股东会会议须知····························································· | 5 | | 2025 | 年第二次临时股东会会议议案····························································· | 6 | | 议案 | 1：关于取消监事会并修订《公司章程》的议案······································ | 6 | | 议案 | 2：关于修订《董事会议事规则》的议案 ...

天眼查商业履历信息显示，益丰大药房连锁股份有限公司，成立于2008年，位于常德市，是一家以从事 卫生为主的企业。企业注册资本121243.2297万人民币，实缴资本12000万人民币。公司法定代表人为高 毅。 通过天眼查大数据分析，益丰大药房连锁股份有限公司共对外投资了33家企业，参与招投标项目1315 次，知识产权方面有商标信息311条，专利信息6条，此外企业还拥有行政许可127个。 来源：金融界 金融界消息 截至2025年8月19日收盘，益丰药房（603939）报收于24.06元，上涨0.8%，换手率0.78%， 成交量9.42万手，成交金额2.27亿元。 资金流向方面，今日主力资金净流入1472.66万元，占比成交额6.49%。其中，超大单净流入1146.64万 元、占成交额5.06%，大单净流入326.03万元、占成交额1.44%，中单净流出流出582.78万元、占成交额 2.57%，小单净流出889.88万元、占成交额3.92%。 益丰药房最新一期业绩显示，截至2025一季报，公司营业总收入60.09亿元、同比增长0.64%，归属净利 润4.49亿元，同比增长10.51%，扣非净利润4.38亿元，同 ...

Market Performance - The pharmaceutical commercial sector increased by 0.67% compared to the previous trading day, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] Individual Stock Performance - Saily Medical (603716) closed at 29.87, up 5.14%, with a trading volume of 409,100 shares and a transaction value of 1.187 billion [1] - Yifeng Pharmacy (603939) closed at 23.87, up 2.14%, with a trading volume of 100,900 shares and a transaction value of 239 million [1] - Other notable performers include Yaoyigou (300937) at 30.10 (+2.03%), Laobaixing (603883) at 18.43 (+1.26%), and Haiwang Biological (000078) at 2.69 (+1.13%) [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 10.8635 million from institutional investors, while retail investors saw a net inflow of 12.0341 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Saily Medical had a net outflow of 95.4222 million from institutional investors, while retail investors contributed a net inflow of 45.8725 million [3] - Guoyao Co. (600511) saw a net inflow of 38.7702 million from institutional investors, but a net outflow of 35.7166 million from retail investors [3] - Other stocks like Zhejiang Zhenyuan (000705) and Ruikang Pharmaceutical (002589) also showed varied capital flows, indicating differing investor sentiments across the sector [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：603939 证券简称：益丰药房 公告编号：2025-073 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 第五届董事会第二十次会议决议公告 鉴于本次会议审议事项时间紧急，豁免召开公司第五届董事会第二十次会议 通知期限的要求，并于 2025 年 8 月 14 日召开会议。 表决结果：9 票同意，0 票反对，0 票弃权。 公司为全资子公司湖北益丰大药房连锁有限公司向银行申请不超过 体授信额度以银行批复为准，授信期内，授信额度可循环使用。 ? 全体董事均亲自出席本次董事会。 ? 无董事对本次董事会议案投反对/弃权票。 ? 本次董事会全部议案均获通过。 一、 董事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 13 日以 电子邮件方式发出第五届董事会第二十次会议通知，会议于 2025 年 8 月 14 日在 湖南省长沙市金洲大道 68 号益丰医药物流园四楼会议室以现场加通讯方式召开， 应参 ...

证券代码：603939 证券简称：益丰药房 公告编号：2025-074 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 表决结果：3 票同意，0 票反对，0 票弃权。 本议案尚需提交公司股东会审议。 益丰大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 13 日以 电子邮件方式发出第五届监事会第十四次会议通知，会议于 2025 年 8 月 14 日在 湖南省长沙市金洲大道 68 号益丰医药物流园五楼会议室召开，应参加表决的监 事 3 人，实际参加表决的监事 3 人，会议以现场方式召开，本次会议的召集、召 开和表决程序符合有关法律、法规和《公司章程》的规定，会议形成的决议合法 有效。 二、 监事会会议审议情况 本次会议由监事会主席陈斌先生召集并主持，采用记名投票方式，通过了如 下议案： 鉴于本次会议审议事项时间紧急，豁免召开公司第五届监事会第十四次会议 通知期限的要求，并于 2025 年 8 月 14 日召开会议。 表决结果：3 票同意，0 票反对，0 票弃权。 公司为全资子公司湖北益丰大药房连锁有限公司向银行申请不超过 体授信额度以银行批复为准，授信期内，授信额度可循 ...

关于2025年第二次临时股东会增加临时提案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603939 证券简称：益丰药房 公告编号：2025-076 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 一、 股东会有关情况 股份类别 股票代码 股票简称 股权登记日 Ａ股 603939 益丰药房 2025/8/14 二、 增加临时提案的情况说明 公司已于2025 年 7 月 31 日公告了股东会召开通知，单独持有19.88%股份的 股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙），在2025 年 8 月 14 日提出临时提案并书面提交股东会召集人。股东会召集人按照《上市公司股东会 规则》有关规定，现予以公告。 宁波梅山保税港区厚信创业投资合伙企业（有限合伙）向公司董事会提出增 加临时提案，提议将《关于公司为子公司申请银行授信提供担保的议案》提交公 司 2025 年第二次临时股东会审议。具体内容详见公司于 2025 年 8 月 15 日披露 在上海证券交易所网站（http://www.s ...